CRISPR
$88.389876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$88.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$3.84 (-4.17%) As of 2:29 PM EDT today
Why Robinhood?
You can buy or sell CRISPR and other stocks, options, and ETFs commission-free!
About CRSP
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. Read More The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland. The listed name for CRSP is CRISPR Therapeutics AG Common Shares.
Employees
304
Headquarters
Zug, Zug
Founded
2014
Market Cap
6.24B
Price-Earnings Ratio
228.28
Dividend Yield
—
Average Volume
1.89M
High Today
$97.10
Low Today
$88.00
Open Price
$96.99
Volume
1.51M
52 Week High
$111.90
52 Week Low
$32.30
Collections
Analyst Ratings
65%
of 17 ratings
Buy
65%
Hold
24%
Sell
12%
CRSP Earnings
-$1.30
-$0.07
$1.17
$2.40
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
— per share
Actual
Expected Nov 3, Pre-Market